ProQR Therapeutics (PRQR)
(Real Time Quote from BATS)
$1.80 USD
+0.02 (0.84%)
Updated Jul 22, 2024 02:46 PM ET
3-Hold of 5 3
D Value A Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRQR 1.80 +0.02(0.84%)
Will PRQR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PRQR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRQR
Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates
PRQR: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK (GSK) Q1 Earnings and Revenues Surpass Estimates
Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates
Is ProQR (PRQR) Stock a Solid Choice Right Now?
Other News for PRQR
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
ProQR Shareholders Approve Key Resolutions
ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)
Buy Rating Affirmed for ProQR on Promising RNA Editing Technology and Solid Financial Footing
ProQR’s Axiomer Platform Technology Shows Promise: Analyst Maintains Buy Rating on Robust Editing Efficacy and Clinical Development Potential